updated 2/22/2013 8:59:32 PM ET 2013-02-23T01:59:32

(Reuters) - Johnson & Johnson said on Friday the U.S. Justice Department is investigating the company's marketing practices related to the hip-replacement product it recalled in 2010 over safety concerns.

Major Market Indices

The diversified healthcare company has also had to recall over-the-counter drugs, contact lenses, heart devices, such as stents, and insulin pump cartridges over the past couple of years.

In August 2010, J&J recalled two types of its ASR metal-on-metal hip implants after they were linked to high failure rates.

Some 93,000 of the ASR hips were sold prior to the recall, which has generated more than 10,000 lawsuits alleging harm from the devices.

J&J said in a regulatory filing that the government is investigating false claims or false statements affecting federal health care programs in connection with the marketing and use of the ASR XL Hip device.

The company said some of its divisions received an informal request in August 2012 from the U.S. attorney's office in Massachusetts and the Justice Department's civil division seeking materials related to the product, the ASR XL Hip device.

J&J said it has voluntarily produced documents in response to the government's informal requests and is fully cooperating with the government's civil investigation.

(Reporting by Neha Alawadhi in Bangalore; Editing by Jackie Frank)

(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.99%
$30K home equity loan FICO 6.18%
$75K home equity loan FICO 5.97%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 11.01%
11.01%
Cash Back Cards 16.34%
16.34%
Rewards Cards 15.80%
15.80%
Source: Bankrate.com
  1. Jump to text

    (Reuters) - Johnson & Johnson said on Fr...

  2. Jump to discussion

    Johnson & Johnson says its marketing practices b...

  3. Jump to data

    See the latest rates around the country